Damien Botsen

639 total citations
29 papers, 171 citations indexed

About

Damien Botsen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Damien Botsen has authored 29 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Physiology. Recurrent topics in Damien Botsen's work include Colorectal Cancer Treatments and Studies (9 papers), Nutrition and Health in Aging (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Damien Botsen is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Nutrition and Health in Aging (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Damien Botsen collaborates with scholars based in France, Belgium and United States. Damien Botsen's co-authors include Olivier Bouché, Marine Perrier, Camille Mazza, Yohann Renard, Éric Bertin, Coralie Barbe, Florian Slimano, Mathias Brügel, Christine Hoeffel and Christophe Portefaix and has published in prestigious journals such as Cancer, Annals of Oncology and Nutrients.

In The Last Decade

Damien Botsen

27 papers receiving 171 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Damien Botsen France	7	89	74	50	30	30	29	171
Shunji Koya Japan	10	154 1.7×	47 0.6×	43 0.9×	21 0.7×	23 0.8×	19	243
Jeroen W. G. Derksen Netherlands	8	66 0.7×	99 1.3×	24 0.5×	23 0.8×	18 0.6×	21	182
Faïza Khemissa France	8	87 1.0×	149 2.0×	47 0.9×	46 1.5×	60 2.0×	24	257
Yumiko Shirai Japan	6	79 0.9×	46 0.6×	18 0.4×	23 0.8×	9 0.3×	14	148
J. Ezenfis France	5	103 1.2×	96 1.3×	47 0.9×	106 3.5×	72 2.4×	10	217
Tim Wilson United Kingdom	6	38 0.4×	86 1.2×	28 0.6×	106 3.5×	36 1.2×	10	176
Lesley Thomas Australia	5	120 1.3×	97 1.3×	67 1.3×	49 1.6×	10 0.3×	8	350
Shayanthan Nanthakumaran United Kingdom	7	83 0.9×	71 1.0×	40 0.8×	73 2.4×	62 2.1×	13	218
Nicole M. Saur United States	8	31 0.3×	65 0.9×	54 1.1×	61 2.0×	17 0.6×	29	178
Jiaan Hu China	9	116 1.3×	47 0.6×	39 0.8×	19 0.6×	56 1.9×	19	273

Countries citing papers authored by Damien Botsen

Since Specialization

Citations

This map shows the geographic impact of Damien Botsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damien Botsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damien Botsen more than expected).

Fields of papers citing papers by Damien Botsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damien Botsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damien Botsen. The network helps show where Damien Botsen may publish in the future.

Co-authorship network of co-authors of Damien Botsen

This figure shows the co-authorship network connecting the top 25 collaborators of Damien Botsen. A scholar is included among the top collaborators of Damien Botsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damien Botsen. Damien Botsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perrier, Marine, Éric Bertin, Damien Botsen, et al.. (2025). Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy. European Journal of Clinical Nutrition. 79(6). 576–586. 1 indexed citations

Rhaiem, Rami, Olivier Bouché, Damien Botsen, et al.. (2025). Hepatic metastases management: A comparative review of surgical resection, thermal ablation, and stereotactic body radiation therapy. European Journal of Cancer. 228. 115691–115691. 1 indexed citations

Ducreux, Michel, Méher Ben Abdelghani, David Tougeron, et al.. (2024). 3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 35. S3–S3. 1 indexed citations

Brügel, Mathias, Kocéila Amroun, Damien Botsen, et al.. (2024). Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted‐screening analysis case‐control study (PESTIPAC). United European Gastroenterology Journal. 12(7). 951–959. 5 indexed citations

Zaanan, Aziz, Olivier Bouché, Christelle de la Fouchardière, et al.. (2023). LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD. Annals of Oncology. 34. S1318–S1318. 8 indexed citations

Brügel, Mathias, Zoubir Djerada, Marine Perrier, et al.. (2023). Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC). Frontiers in Pharmacology. 14. 1137791–1137791. 5 indexed citations

Brügel, Mathias, et al.. (2023). Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pancreatic adenocarcinoma: A retrospective single-centre observational study. Pancreatology. 23(4). 403–410.

Mazard, Thibault, François Ghiringhelli, Anke Winter, et al.. (2023). LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study. Annals of Oncology. 34. S1270–S1270. 2 indexed citations

Botsen, Damien, Mathias Brügel, Éric Bertin, et al.. (2022). Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX). Nutrients. 14(21). 4448–4448. 3 indexed citations

10.

Gower‐Rousseau, Corinne, Damien Botsen, Maxime Hentzien, et al.. (2022). Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?. BMC Cancer. 22(1). 1219–1219. 6 indexed citations

11.

Evrard, Camille, Thomas Aparicio, Émilie Soularue, et al.. (2022). Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines. 10(5). 1211–1211. 4 indexed citations

12.

Brügel, Mathias, Damien Botsen, Camille Boulagnon‐Rombi, et al.. (2022). One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV). Cancer Medicine. 11(24). 4865–4879. 3 indexed citations

13.

Perrier, Marine, Coralie Barbe, Camille Mazza, et al.. (2021). Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study). Supportive Care in Cancer. 30(1). 207–215. 9 indexed citations

14.

Ducreux, Michel, Aurélie Parzy, Méher Ben Abdelghani, et al.. (2021). 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 32. S580–S581. 1 indexed citations

15.

Botsen, Damien, et al.. (2021). A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. Journal of Oncology Pharmacy Practice. 28(1). 247–249. 1 indexed citations

16.

Fouchardière, Arnaud de la, Pascal Hammel, Angélique Vienot, et al.. (2020). 1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma. Annals of Oncology. 31. S954–S955. 3 indexed citations

17.

Barbe, Coralie, Mathias Brügel, Vincent Hautefeuille, et al.. (2020). Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.. Digestive and Liver Disease. 52(6). 658–667. 6 indexed citations

18.

Botsen, Damien, et al.. (2019). Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. Supportive Care in Cancer. 27(9). 3179–3182. 2 indexed citations

19.

Barbe, Coralie, Camille Mazza, Marine Perrier, et al.. (2019). Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Medicine. 8(8). 3677–3684. 35 indexed citations

20.

Botsen, Damien, Coralie Barbe, Camille Mazza, et al.. (2018). Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients. BMC Cancer. 18(1). 955–955. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact